GIP and GLP-1 receptor co-agonist
CT-388 6.0 mg injection
CT388_SC_6p0MG_OTHER
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.67 (0.22 to 113) | 0.22 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.68 (0.10 to 18.99) | 0.68 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.16 (0.59 to 61.95) | 0.40 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.47 (0.10 to 16.41) | 0.56 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.22 (0.00 to 4.22) | 0.86 |